Market Cap 238.75M
Revenue (ttm) 82.03M
Net Income (ttm) -65.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -80.19%
Debt to Equity Ratio 0.00
Volume 260,200
Avg Vol 469,380
Day's Range N/A - N/A
Shares Out 28.42M
Stochastic %K 45%
Beta 2.44
Analysts Strong Sell
Price Target $18.33

Company Profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address orni...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 900 2660
Address:
10285 Science Center Drive, San Diego, United States
bigchouse
bigchouse Apr. 29 at 4:47 PM
$ARCT I'm waiting for our day in the sun, too. Wall Street’s Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets The biotech and health-tech landscape is entering a new acceleration phase, driven by regulatory momentum, AI integration, and a surge in precision medicine.
1 · Reply
MaxCorona
MaxCorona Apr. 28 at 12:13 PM
$ARCT and back to 7. no news, nothing. Are they still working on anything?
2 · Reply
bigchouse
bigchouse Apr. 27 at 5:13 PM
$ARCT https://www.ft.com/content/2cf36d19-ebd8-4c99-bb6f-d32abb7e0aba
0 · Reply
bigchouse
bigchouse Apr. 24 at 8:16 PM
$ARCT To our Stockholders: We are pleased to invite you to attend the 2026 annual meeting of stockholders (the “Annual Meeting”) of Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”), to be held on June 5, 2026 at 9:00 a.m. Pacific Time, at https://www.cstproxy.com/arcturusrx/2026. The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted exclusively on the internet. No physical meeting will be held. Details regarding how to attend the entirely virtual Annual Meeting and the business to be conducted at the Annual Meeting are more fully described in the accompanying notice of annual meeting of stockholders and proxy statement. ......... Sincerely, Dr. Moncef Slaoui Chairman of the Board
3 · Reply
Nganlm
Nganlm Apr. 23 at 11:58 AM
$ARCT https://www.pacermonitor.com/public/case/60277994/Arcturus_Therapeutics,_Inc_v_AbbVie_Inc_et_al Note that yesterday 22 April, there was joint motion for extension of time to file answer. The defendants in this case ie Abbvie, probably need more time to reassess strategy.
0 · Reply
DragonAlgo
DragonAlgo Apr. 23 at 8:12 AM
🐉 $ARCT PUT — DragonAlgo® Signal Contract: ARCT PUT Expiry: 2026-05-15 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $0.30 Stop: $0.22 TP1: $0.39 TP2: $0.51 TP3: $0.72 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
bigchouse
bigchouse Apr. 23 at 6:16 AM
$ARCT CDC won’t publish report showing covid shots cut likelihood of hospital visits The report had cleared the agency’s scientific-review process, which includes dozens of scientists, according to two of the three people who spoke to The Post. Stopping an MMWR report at that stage is highly unusual, former CDC officials say. https://www.washingtonpost.com/health/2026/04/22/covid-vaccine-report-blocked-cdc-mmwr/
0 · Reply
DragonAlgo
DragonAlgo Apr. 22 at 1:45 PM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-05-15 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $0.40 Stop: $0.29 TP1: $0.52 TP2: $0.68 TP3: $0.96 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 20 at 1:32 PM
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech $OTLC $SRPT $ALNY $ARCT $DNLI https://ibn.fm/uOEoD
0 · Reply
DragonAlgo
DragonAlgo Apr. 20 at 5:08 AM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-06-18 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $2.23 Stop: $1.60 TP1: $2.89 TP2: $3.78 TP3: $5.34 🔗 https://dragonalgo.com
0 · Reply
Latest News on ARCT
Arcturus Therapeutics to Attend Upcoming Investor Conference

Mar 5, 2026, 9:00 AM EST - 2 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conference


Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2025


Arcturus Therapeutics to Attend Upcoming Investor Conferences

Nov 4, 2025, 4:01 PM EST - 6 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences


Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 9 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2025


Arcturus Therapeutics Holdings Transcript: Status Update

Jun 30, 2025, 12:00 PM EDT - 10 months ago

Arcturus Therapeutics Holdings Transcript: Status Update


Arcturus Therapeutics Holdings Transcript: Status Update

Apr 16, 2025, 11:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Status Update


Arcturus Therapeutics Holdings Transcript: Fireside Chat

Apr 11, 2025, 12:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Fireside Chat


Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.


bigchouse
bigchouse Apr. 29 at 4:47 PM
$ARCT I'm waiting for our day in the sun, too. Wall Street’s Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets The biotech and health-tech landscape is entering a new acceleration phase, driven by regulatory momentum, AI integration, and a surge in precision medicine.
1 · Reply
MaxCorona
MaxCorona Apr. 28 at 12:13 PM
$ARCT and back to 7. no news, nothing. Are they still working on anything?
2 · Reply
bigchouse
bigchouse Apr. 27 at 5:13 PM
$ARCT https://www.ft.com/content/2cf36d19-ebd8-4c99-bb6f-d32abb7e0aba
0 · Reply
bigchouse
bigchouse Apr. 24 at 8:16 PM
$ARCT To our Stockholders: We are pleased to invite you to attend the 2026 annual meeting of stockholders (the “Annual Meeting”) of Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”), to be held on June 5, 2026 at 9:00 a.m. Pacific Time, at https://www.cstproxy.com/arcturusrx/2026. The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted exclusively on the internet. No physical meeting will be held. Details regarding how to attend the entirely virtual Annual Meeting and the business to be conducted at the Annual Meeting are more fully described in the accompanying notice of annual meeting of stockholders and proxy statement. ......... Sincerely, Dr. Moncef Slaoui Chairman of the Board
3 · Reply
Nganlm
Nganlm Apr. 23 at 11:58 AM
$ARCT https://www.pacermonitor.com/public/case/60277994/Arcturus_Therapeutics,_Inc_v_AbbVie_Inc_et_al Note that yesterday 22 April, there was joint motion for extension of time to file answer. The defendants in this case ie Abbvie, probably need more time to reassess strategy.
0 · Reply
DragonAlgo
DragonAlgo Apr. 23 at 8:12 AM
🐉 $ARCT PUT — DragonAlgo® Signal Contract: ARCT PUT Expiry: 2026-05-15 | Strike: $7.50 | Type: PUT Option Plan (premium): Entry: $0.30 Stop: $0.22 TP1: $0.39 TP2: $0.51 TP3: $0.72 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
bigchouse
bigchouse Apr. 23 at 6:16 AM
$ARCT CDC won’t publish report showing covid shots cut likelihood of hospital visits The report had cleared the agency’s scientific-review process, which includes dozens of scientists, according to two of the three people who spoke to The Post. Stopping an MMWR report at that stage is highly unusual, former CDC officials say. https://www.washingtonpost.com/health/2026/04/22/covid-vaccine-report-blocked-cdc-mmwr/
0 · Reply
DragonAlgo
DragonAlgo Apr. 22 at 1:45 PM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-05-15 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $0.40 Stop: $0.29 TP1: $0.52 TP2: $0.68 TP3: $0.96 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 20 at 1:32 PM
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech $OTLC $SRPT $ALNY $ARCT $DNLI https://ibn.fm/uOEoD
0 · Reply
DragonAlgo
DragonAlgo Apr. 20 at 5:08 AM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-06-18 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $2.23 Stop: $1.60 TP1: $2.89 TP2: $3.78 TP3: $5.34 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 17 at 5:58 PM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-06-18 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $2.23 Stop: $1.60 TP1: $2.89 TP2: $3.78 TP3: $5.34 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
Choice79
Choice79 Apr. 17 at 2:37 PM
$ARCT I bet a lot of short covering is going on. Too dangerous to be holding a short position with all the potential carters coming in the next few months.
1 · Reply
Jasper2017
Jasper2017 Apr. 17 at 2:35 PM
$ARCT looking promising ✅️
0 · Reply
Dr_Feel_Good
Dr_Feel_Good Apr. 17 at 2:09 AM
$ARCT 8 is a lucky number 🌬️🎲
1 · Reply
bigchouse
bigchouse Apr. 16 at 5:36 PM
$ARCT Pfizer should be out of business. https://x.com/ShannonJoyRadio/status/2044799210365538591#m
0 · Reply
bigchouse
bigchouse Apr. 15 at 5:11 PM
$ARCT Pfizer should be shut down. Pfizer's Covid injection saved ZERO LIVES in its "clinical trial". https://www.fda.gov/media/151733/download
0 · Reply
bigchouse
bigchouse Apr. 15 at 5:02 AM
$ARCT Per Grok: Potential Advantages of Jury Trials for Biotech Companies As a plaintiff: Juries can deliver large awards when the company demonstrates clear harm, such as patent infringement or anticompetitive behavior by rivals. Examples include: Regeneron securing a ~$407 million antitrust jury verdict against Amgen over PCSK9 inhibitors. Emotional or narrative appeal: Juries can be swayed by stories of innovation, patient impact, or corporate misconduct by opponents. They sometimes award higher damages than judges in cases with sympathetic facts. Leverage for settlement: The threat of an unpredictable jury can push opponents to settle favorably before trial. Public validation: A jury win can boost credibility, attract investors, or deter future challenges in a competitive field.
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 6:05 PM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-04-17 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $1.20 Stop: $0.86 TP1: $1.56 TP2: $2.04 TP3: $2.88 🔗 https://dragonalgo.com
0 · Reply
Nganlm
Nganlm Apr. 14 at 11:35 AM
$ARCT https://www.pacermonitor.com/public/case/60277994/Arcturus_Therapeutics,_Inc_v_AbbVie_Inc_et_al Latest filing by Arcturus versus Abbvie.
1 · Reply
bigchouse
bigchouse Apr. 14 at 4:45 AM
$ARCT Pfizer again. Shut Pfizer down. "HHS records show that as early as October 2022, federal health officials identified a potential connection between the Pfizer-BioNTech COVID-19 bivalent booster and ischemic stroke for individuals over the age of 65," Johnson wrote. An ischemic stroke means a blockage of blood to the brain. Between November 2022 and March 2023, seven separate analyses of incoming data flagged the same stroke signal — specifically in adults over 65. CDC data cited by Johnson shows 226 stroke cases reported between August 2022 and February 2023, with additional cases surfacing throughout 2023 and 2024. https://www.zerohedge.com/medical/biden-fda-knew-about-covid-vaccine-stroke-risk-and-kept-americans-dark
0 · Reply
macroaxis
macroaxis Apr. 12 at 3:25 PM
$ARCT - Arcturus options price alert: Put open interest has decreased to 1,350 contracts https://www.macroaxis.com/stock-options/ARCT/Arcturus-Therapeutics-Holdings?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
bigchouse
bigchouse Apr. 12 at 11:22 AM
$ARCT Pfizer should be pulled from the market.
3 · Reply